EUVIMEDEUVIMED entdecken
Open Access

CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib by regulating G2/M cell cycle arrest

Wen Cao, Shunnan Yao, Anqi Li, Haoguang Chen, Enfan Zhang, Liqin Cao, Jinna Zhang, Yifan Hou, Zhenfeng Dai, Jing Chen, Xi Huang, Li Yang und 1 weitere

Journal of Zhejiang University-SCIENCE B · 2023-05 · 24 (5) · 442-454

DOI: 10.1631/jzus.b2200465 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Zhejiang University-SCIENCE B, online erschienen am 22.05.2023. Verfasst von Wen Cao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Bortezomib, ErbB Receptors, Histone Deacetylase Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: the National Natural Science Foundation of China, the Zhejiang Key Research and Development Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBortezomibErbB ReceptorsHistone Deacetylase InhibitorsMultiple MyelomaHumansApoptosisCell Line, TumorCell ProliferationG2 Phase Cell Cycle CheckpointsHistone DeacetylasesM CellsHydroxamic AcidsQuinazolines

Stichwörter der Autor:innen

BortezomibCUDC-101Cell cycleEpidermal growth factor receptor (EGFR)Multiple myeloma

Substanzen

Antineoplastic AgentsBortezomibErbB ReceptorsHistone Deacetylase InhibitorsHistone Deacetylases7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamideHydroxamic AcidsQuinazolinesEGFR protein, human

Autor:innen und Institutionen

  • Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
  • Institute of Hematology, Zhejiang University, Hangzhou 310058, China.
  • School of Medicine, Zhejiang University, Hangzhou 310058, China.
  • Institute of Hematology, Zhejiang University, Hangzhou 310058, China. caiz@zju.edu.cn, liyanghz@zju.edu.cn.
  • Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China. caiz@zju.edu.cn.
  • Institute of Hematology, Zhejiang University, Hangzhou 310058, China. caiz@zju.edu.cn.

Förderung

  • the National Natural Science Foundation of China
  • the Zhejiang Key Research and Development Project

Zitieren

APA

Cao, W., Yao, S., Li, A., Chen, H., Zhang, E., Cao, L., Zhang, J., Hou, Y., Dai, Z., Chen, J., Huang, X., Yang, L., & Cai, Z. (2023). CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib by regulating G2/M cell cycle arrest. Journal of Zhejiang University-SCIENCE B, 24(5), 442-454. https://doi.org/10.1631/jzus.b2200465

Vancouver

Cao W, Yao S, Li A, Chen H, Zhang E, Cao L, et al. CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib by regulating G2/M cell cycle arrest. Journal of Zhejiang University-SCIENCE B. 2023;24(5):442-454. doi:10.1631/jzus.b2200465

BibTeX
@article{Cao2023,
  author = {Cao, Wen and Yao, Shunnan and Li, Anqi and Chen, Haoguang and Zhang, Enfan and Cao, Liqin and Zhang, Jinna and Hou, Yifan and Dai, Zhenfeng and Chen, Jing and Huang, Xi and Yang, Li and Cai, Zhen},
  title = {CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib by regulating G2/M cell cycle arrest},
  journal = {Journal of Zhejiang University-SCIENCE B},
  year = {2023},
  volume = {24},
  number = {5},
  pages = {442--454},
  doi = {10.1631/jzus.b2200465}
}
Kostenlos starten →